Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 8:10:1326091.
doi: 10.3389/fcvm.2023.1326091. eCollection 2023.

A more-Comers populAtion trEated with an ultrathin struts polimer-free Sirolimus stent: an Italian post-maRketing study (the CAESAR registry)

Giuseppe Tarantini #  1 , Francesco Cardaioli #  1 , Giuseppe De Iaco  2 , Bernardino Tuccillo  3 , Maria Carmen De Angelis  3 , Ciro Mauro  4 , Marco Boccalatte  5 , Antonio Trivisonno  6 , Flavio Ribichini  7 , Giuseppe Vadalà  8 , Giuseppe Caramanno  9 , Marco Caruso  10 , Mario Lombardi  11 , Dionigi Fischetti  12 , Alessandro Danesi  13 , Leonardo Abbracciavento  14 , Giulia Lorenzoni  15 , Dario Gregori  15 , Andrea Panza  1 , Luca Nai Fovino  1 , Giovanni Esposito  16
Affiliations

A more-Comers populAtion trEated with an ultrathin struts polimer-free Sirolimus stent: an Italian post-maRketing study (the CAESAR registry)

Giuseppe Tarantini et al. Front Cardiovasc Med. .

Abstract

Introduction: The use of contemporary drug-eluting stents (DES) has significantly improved outcomes of patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). However, concerns exist regarding the long-term proinflammatory effects of durable polymer coatings used in most DES, potentially leading to long-term adverse events. First-generation polymer-free stent technologies, such as sirolimus- and probucol-eluting stents (PF-SES), have shown an excellent safety and efficacy profile. The aim of this study was to evaluate the safety and efficacy of the new ultrathin Coroflex ISAR NEO PF-SES, in a more-comers PCI population.

Methods: The CAESAR (a more-Comers populAtion trEated with an ultrathin struts polimer-free Sirolimus stent: An Italian post-maRketing study) registry is a multicenter, prospective study conducted in Italy, enrolling more-comers CAD patients undergoing PCI with the Coroflex ISAR NEO stent. Patients with left main (LM) disease, cardiogenic shock (CS), or severely reduced left-ventricular ejection fraction (LVEF) were excluded. The primary endpoint was target-lesion revascularization (TLR) at 1 year.

Results: A total of 425 patients were enrolled at 13 centers (mean age 66.9 ± 11.6 years, Diabetes mellitus 29%, acute coronary syndrome 67%, chronic total occlusion 9%). Of these, 40.9% had multivessel disease (MVD) and in 3.3% cases, the target lesion was in-stent restenosis (ISR). Clinical device success was reached in 422 (99.6%) cases. At 1 year, only two (0.5%) subjects presented ischemia-driven TLR. The 1-year rates of target vessel revascularization and MACE were 0.5% and 5.1%, respectively. Major bleeding was observed in four (1.0%) patients.

Conclusion: In this multicenter, prospective registry, the use of a new ultrathin Coroflex ISAR NEO PF-SES in a more-comers PCI population showed good safety and efficacy at 1 year.

Keywords: PCI; acute coronary syndrome (ACS); coronary artery disease; drug-eluting stent (DES); ultrathin struts.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

Figure 1
Figure 1
The Kaplan–Meier curve for MACE.
See this image and copyright information in PMC

References

    1. Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med. (2010) 363(24):2310–9. 10.1056/NEJMoa1009406 - DOI - PubMed
    1. Kufner S, Ernst M, Cassese S, Joner M, Mayer K, Colleran R, et al. 10-year outcomes from a randomized trial of polymer-free versus durable polymer drug-eluting coronary stents. J Am Coll Cardiol. (2020) 76(2):146–58. 10.1016/j.jacc.2020.05.026 - DOI - PubMed
    1. Tarantini G, Fovino LN, Varbella F, Trabattoni D, Caramanno G, Trani C, et al. A large, prospective, multicentre study of left main PCI using a latest-generation zotarolimus-eluting stent: the ROLEX study. EuroIntervention. (2023) 18(13):e1108–19. 10.4244/EIJ-D-22-00454 - DOI - PMC - PubMed
    1. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. (2019) 40(2):87–165. 10.1093/eurheartj/ehy394 - DOI - PubMed
    1. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, et al. The pathology of neoatherosclerosis in human coronary implants. J Am Coll Cardiol. (2011) 57(11):1314–22. 10.1016/j.jacc.2011.01.011 - DOI - PMC - PubMed